Top news
-
12-September-2023
A new Russian drug for the relief of headaches caused by migraine attacks, Relonova® (INN Rizatriptan), developed and produced by the Russian pharmaceutical company NovaMedica, has become available for purchase on online pharmacy websites, which will make it easier for patients to access it.
-
Production of one of the world's most sought-after drugs for migraine therapy starts in Moscow
12-July-2023
The Russian pharmaceutical company NovaMedica has announced the production and market launch of the first large batch of the drug Relonova® intended for relief of migraine-associated headaches. The drug is based on the Rizatriptan molecule, which for the first time is fully localized in Russia, from development and manufacturing to introduction in the specialist prescription practice. Rizatriptan is one of the most sought-after molecules in the world for relief and alleviation of migraine symptoms.
Media about us
-
Production of one of the world’s most sought-after drugs for migraine therapy starts in Moscow
13-July-2023
-
Production of one of the world’s most sought-after drugs for migraine therapy starts in Moscow
12-July-2023
-
12-April-2023
-
NovaMedica will produce migraine drug Relonova in Moscow
23-March-2023
Our news
-
21-September-2023
-
September 21 is World Alzheimer's Day. NovaMedica supports this awareness raising campaign
21-September-2023
-
12-September-2023
Industry news
-
AI-supported spectroscopy delivers superior pharmaceutical packaging QC
03-October-2023
-
Lymphoma maintenance therapy delivers promise in CTCL
03-October-2023
-
02-October-2023